Revisor Wealth Management’s NeuroOne Medical Technologies NMTC Stock Holding History

Revisor Wealth Management’s Portfolio NMTC Stock Details NMTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.2K	Buy	+3,263	New	+$15.7K	﹤0.01%	324

Other funds holding NMTC

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Revisor Wealth Management's NMTC Position: Q1 2026 in Review

Revisor Wealth Management opened a new position in NeuroOne Medical Technologies (NMTC) in Q1 2026: 3,263 shares worth $15.2K. The stake represents ﹤0.01% of the portfolio and ranks #324 among its holdings.

32 funds tracked by Wall St. Rank hold NMTC as of Q1 2026.

Revisor Wealth Management held 3,263 shares of NeuroOne Medical Technologies worth $15.2K as of Q1 2026.
NeuroOne Medical Technologies was a new Revisor Wealth Management position in Q1 2026.
NeuroOne Medical Technologies made up ﹤0.01% of Revisor Wealth Management's portfolio in Q1 2026, its #324 holding.
32 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q1 2026.

Based on Revisor Wealth Management's 13F filing for Q1 2026, filed 27 Apr 2026.